Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zolmitriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 11/20 | 1.00 |
| ▸ | HTR1B known ✓ | P28222 | 11/20 | 1.00 |
| ▸ | HTR1A | P08908 | 10/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HTR1F | P30939 | 2/20 | 0.63 |
| ▸ | HTR5A | P47898 | 4/20 | 0.54 |
| ▸ | HTR2C | P28335 | 3/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | HTR1E | P28566 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zolmitriptan SCHEMBL29835946 | 1.00 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL14861150 | 1.00 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL40595 | 1.00 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL33336 | 1.00 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL4427888 | 1.00 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL1246512 | 1.00 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL2377949 | 0.99 | HTR1D (0.98) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL2458156 | 0.99 | HTR1D (0.98) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL2540996 | 0.96 | HTR1D (0.92) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| Zolmitriptan SCHEMBL2376692 | 0.95 | HTR1D (0.90) | HTR1DHTR1BHTR1AHTR2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631569-A2 | ALGINATE FILM COMPRISING A TRIPTAN | Klaria Pharma Holding AB (SE) | 2025-10-15 | — | — | EP | claimed |
| WO-2023055939-A9 | APPARATUS, SYSTEMS AND METHODS FOR TRANSDERMAL DRUG DELIVERY, PERMEABILITY ENHANCEMENT AND AUGMENTATION | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2024-04-25 | — | — | WO | claimed |
| US-11638809-B2 | Triptan microporation delivery system | Passport Technologies, Inc. (US) | 2023-05-02 | — | — | US | claimed |
| WO-2023055939-A1 | APPARATUS, SYSTEMS AND METHODS FOR TRANSDERMAL DRUG DELIVERY, PERMEABILITY ENHANCEMENT AND AUGMENTATION | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2023-04-06 | — | — | WO | claimed |
| WO-2023288110-A1 | ROMIDEPSIN AS A THERAPEUTIC AGENT FOR NERVE-INJURY INDUCED NEUROPATHIC PAIN AND SPASTICITY | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2023-01-19 | — | — | WO | claimed |
| US-12616752-B2 | Pharmaceutical compositions comprising meloxicam | AXSOME THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12611413-B2 | Pharmaceutical compositions comprising meloxicam | AXSOME THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4716570-A1 | RESPIRATORY DELIVERY DEVICE | De Motu Cordis Pty Ltd (AU) | 2026-04-01 | — | — | EP | disclosed |
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| EP-4712803-A1 | MIST INHALATION POD FOR DELIVERING A THERAPEUTIC | Shaheen Innovations Holding Limited (AE) | 2026-03-25 | — | — | EP | disclosed |
| US-20260077048-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | AXSOME THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260034318-A1 | MIST INHALATION POD FOR DELIVERING A THERAPEUTIC | SHAHEEN INNOVATIONS HOLDING LTD (AE) | 2026-02-05 | — | — | US | disclosed |
| US-20220088027-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-03-24 | — | — | US | disclosed |
| EP-3962455-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | Orexo AB (SE) | 2022-03-09 | — | — | EP | disclosed |
| EP-3962522-A1 | TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES | H. Lundbeck A/S (DK) | 2022-03-09 | — | — | EP | disclosed |
| US-11266657-B2 | Pharmaceutical compositions comprising meloxicam | AXSOME THERAPEUTICS, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20220054498-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-02-24 | — | — | US | disclosed |
| US-11247001-B2 | Delivery device with cantilever structure and associated method of use | De Motu Cordis Pty Ltd (AU) | 2022-02-15 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-20220023551-A1 | METHODS AND DEVICES FOR CONTROLLED DRUG VAPORIZATION | THE TRUSTEES OF PRINCETON UNIVERSITY | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616752-B2 | Pharmaceutical compositions comprising meloxicam | SLC10A2, SLC10A1, CALCA | HTR1D 211/4885HTR1B 528/4885HTR1A 194/4885 |
| US-20260077048-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | SLC10A2, SLC10A1, CYP2C9 | HTR1D 73/4885HTR1B 316/4885HTR1A 121/4885 |
| US-20220088027-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | CA9, CALCA, MC3R | HTR1D 443/4885HTR1B 904/4885HTR1A 163/4885 |
| US-20220054498-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | CA9, CALCA, MC3R | HTR1D 443/4885HTR1B 904/4885HTR1A 163/4885 |
| US-11266657-B2 | Pharmaceutical compositions comprising meloxicam | CA9, CALCA, MC3R | HTR1D 443/4885HTR1B 904/4885HTR1A 163/4885 |
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | HTR1D 217/4885HTR1B 91/4885HTR1A 291/4885 |
| US-20260034318-A1 | MIST INHALATION POD FOR DELIVERING A THERAPEUTIC | AQP1, MUC1, AQP4 | HTR1D 1732/4885HTR1B 3133/4885HTR1A 2290/4885 |
| US-12611413-B2 | Pharmaceutical compositions comprising meloxicam | SLC10A2, SLC10A1, MC3R | HTR1D 404/4885HTR1B 770/4885HTR1A 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.